affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
shut down · 2026-03-06T00:00:00.000Z
Quality collapse on retatrutide batches over 15 months culminated in counterfeit detection by Janoshik; federal pressure followed; operations ceased.
Peptide Sciences ceased operations on March 6, 2026 after a slow-motion
quality collapse that played out in public via Janoshik's third-party
testing database. The vendor was, until late 2024, the most-recommended
research-peptide source on r/Peptides — a status earned over years of
broad catalog, consistent COA practices, and competitive pricing.
That position is what made the 2025 trajectory damaging: the community
trusted Peptide Sciences enough to keep buying through declining quality
signals, and the data trail Janoshik built over fifteen months is now the
clearest documented case of a major vendor's quality erosion preceding
shutdown.
The Janoshik trail
Across December 2024 and March 2026, Janoshik recorded 37 retatrutide
samples submitted under Peptide Sciences batches that failed their
labelled purity claims. The failure pattern was not random:
Early 2025: results ran 2–4 percentage points below claimed purity.
Within typical cross-lab tolerance; not a five-alarm signal individually.
Mid 2025: failures clustered into specific lot ranges. Multiple buyers
posting Janoshik QRs on r/Peptides reported under-spec results from
the same batch IDs.
Late 2025: at least one batch returned a mass-spec identity result
inconsistent with retatrutide — Janoshik's terminology for an
identity mismatch, the practical definition of a counterfeit.
The cumulative trend was visible to any reader of the Janoshik
public-tests database. Several r/Peptides moderators surfaced the
pattern in mid-2025 threads, but Peptide Sciences' brand inertia kept
purchase volume high.
Federal pressure
The formal trigger for the March 2026 closure was federal pressure
documented in PeptideLaws.com's FDA timeline
and The Peptide Catalog's reporting.
Both sources cite mounting regulator attention that paralleled the
quality collapse. The specific enforcement action that ended operations
has not been published in full — Peptide Sciences shut down rather than
respond publicly.
This is structurally similar to the Amino Asylum (June 2025) and
Paradigm Peptides (December 2025) closures: federal action
arrives after public quality signals are already widespread, and the
vendor's exit is faster than the regulatory record.
Lessons for buyers
Three operational rules emerge from the Peptide Sciences case, all
visible from public data alone:
Trend, not single failures. A vendor with one failed COA result
is statistical noise. A vendor with five failures across three months
on a flagship SKU is a leading indicator.
Identity confirmation, not just purity. HPLC purity numbers can
look acceptable on a counterfeit molecule. Janoshik's mass-spec
identity tests are the gating signal — vendors whose COAs only
include HPLC are concealing the dimension that matters most for novel
compounds like retatrutide.
Brand inertia is a buyer's risk. Peptide Sciences' community
reputation kept buyers loyal months after the data turned. The
instinct "I've ordered from them before, they're fine" is precisely
the bias the audit framework exists to override.
Where the catalog migrated
The displaced reader population in early 2026 has primarily moved to:
Limitless Biotech (formerly Limitless Life Nootropics) — current
preview profile on this site
Particle Peptides — current preview profile on this site
Ascension Peptides — newer entrant filling the GLP-1 segment;
current preview profile
Each has a current audit page with the relevant auditTier: public-data
flag while we ramp first-hand testing through the M1 cycle.